ArticlePloS one2026
A Darwinian model for the evolution of drug resistance to long-acting PrEP during an early HIV infection.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting the evolution of drug resistance remains a central challenge in HIV prevention and treatment. Evolutionary trade-offs, i.e., the fitness costs of resistance, shift as drug-selective pressure changes, a complexity amplified by fluctuating drug concentrations during long-acting prophylaxis. We develop a Darwinian evolutionary game theory model of early HIV infection under bimonthly pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA). This work introduces a mathematical framework that couples within-host viral dynamics with adaptive evolutionary processes in a time-dependent environment to study resistance evolution under long-acting PrEP. The model incorporates the dual transmission pathways of HIV: free virion spread and direct cell-to-cell transfer through virological synapses. We quantify how resistance mutations alter viral fitness across these modes. We formulate a deterministic within-host model that explicitly incorporates the dual transmission pathways and introduce continuous resistance traits governing infectivity and drug susceptibility for each pathway. T-cell parameter estimates are informed by data assimilation using acute-stage HIV infection data. CAB-LA is modeled with time-periodic pharmacokinetics-pharmacodynamics (PK/PD), yielding dynamic fitness seascapes rather than static fitness landscapes. Time-varying drug pressure introduces a trade-off between drug resistance and infectivity, driving competition among strains that favor different transmission strategies. Our results show that fluctuating drug concentrations reshape evolutionary outcomes, generating dynamic strain competition and altering the effectiveness of long-acting PrEP in blocking infection. The model reveals threshold behavior in drug robustness to mutation, identifies conditions leading to viral control, viral escape, and delayed seroconversion, and demonstrates that resistance evolution depends on both transmission pathway and initial trait configuration. These findings provide a mechanistic explanation for delayed HIV detectability observed in CAB-LA clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.